Download Free Sample Report

The global senolytic drug market size is projected to reach $10.2 billion by 2030, from $1.5 billion in 2022, growing at a CAGR of 25.3% during 2022-2030.​

This report contains market size and forecasts of Senolytic Drug in Global, including the following market information:

• Global Senolytic Drug Market Revenue, 2018-2023, 2023-2030, ($ millions)
• Global top five companies in 2022 (%)

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
FOXO4-related Peptides Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Senolytic Drug include AgeX Therapeutics, Inc., Cleara Biotech, Eternans Ltd., FoxBio Inc, Numeric Biotech, T.A. Sciences, Inc. and Recursion Pharmaceuticals, Inc., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Senolytic Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

• FOXO4-related Peptides
• Bcl-2 Family Inhibitors
• Navitoclax
• Dasatinib and Quercetin
• Others

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis

• Key companies Senolytic Drug revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Senolytic Drug revenues share in global market, 2022 (%)

key players include:

• AgeX Therapeutics, Inc.
• Cleara Biotech
• Eternans Ltd.
• FoxBio Inc
• Numeric Biotech
• T.A. Sciences, Inc.
• Recursion Pharmaceuticals, Inc.